University of Miami

The University of Miami appears in the evidence as an institutional center linking hepatology, nephrology, dialysis medicine, and transplantation. Its School of Medicine in Miami is associated with contributors who examine hepatitis C virus infection across the continuum from diagnosis and liver disease to dialysis outcomes and kidney-transplant candidacy. The institution’s significance lies less in a single institutional policy than in its position within the clinical and research network that turns HCV from a laboratory finding into a condition requiring coordinated assessment of viral activity, extrahepatic disease, liver injury, treatment toxicity, and transplant eligibility.

Institutional Presence and Clinical Scope

The University of Miami is identified through the Division of Hepatology at its School of Medicine, while the volume separately associates the University of Miami Miller School of Medicine with nephrology and hypertension. Together, these references place the university within the multidisciplinary care of patients whose HCV infection intersects with chronic kidney disease and end-stage renal disease. The surrounding evidence treats HCV as a systemic disease: it can affect the liver while also inducing autoimmune, dermatological, and renal disease, making a single-organ approach inadequate.

This institutional setting reflects the book’s broader clinical architecture. HCV-related care requires confirmation of infection, assessment of liver fibrosis and extrahepatic complications, consideration of antiviral therapy, and adjustment of decisions for patients receiving long-term dialysis or being evaluated for kidney transplantation. The University of Miami therefore appears as part of a medical environment in which hepatology and nephrology must continually negotiate the competing risks of untreated infection, treatment toxicity, immunosuppression, and graft dysfunction.

Research and Knowledge Production

The University of Miami is connected to evidence concerning the biochemical and clinical manifestations of HCV-related liver disease in patients undergoing long-term dialysis. In that population, liver disease is often asymptomatic, because fatigue, asthenia, cognitive impairment, anemia, and other complaints may already be common consequences of dialysis and its comorbidities. The clinical problem is consequently not limited to recognizing symptoms; it also requires interpreting laboratory abnormalities and determining whether apparently compensated disease conceals progressive hepatic injury.

The book places this work within a larger research tradition in which HCV infection is studied through both virologic and clinical distinctions. Chronic active infection requires anti-HCV positivity together with detectable HCV RNA, while evaluation of established infection must address hepatic impact and extrahepatic disease, including cryoglobulinemia-associated vasculitis. Noninvasive fibrosis measures, including FibroScan-based liver-stiffness assessment, may reduce the need for liver biopsy and allow repeated follow-up, but the evidence concerning transplant candidates still emphasizes the distinctive diagnostic value of biopsy.

Dialysis, Quality of Life, and Treatment Burden

The University of Miami’s association with dialysis-focused hepatology research also places it within the debate over outcomes that extend beyond mortality. HCV-positive patients receiving long-term dialysis may have diminished quality of life, and one study of 165 dialysis patients found an independent relationship between anti-HCV positivity and a lower mental component summary score on the SF-36 questionnaire, without a corresponding association with the physical component summary score. The evidence links this mental burden to depression, concerns about long-term health, fatigue, cognitive impairment, and the psychological effects of receiving an HCV diagnosis while already living with dialysis.

Treatment itself introduces another layer of risk. Interferon-based therapy can produce flu-like symptoms, anemia, neutropenia, depression, anxiety, and other neuropsychiatric effects. These toxicities led to dose reduction in roughly 35–42% of patients and treatment discontinuation in about 30% in the cited evidence. For a university-based clinical program, the implication is practical as well as scientific: an antiviral decision cannot be based solely on viral clearance or liver histology, because treatment may alter quality of life and may be difficult to sustain in patients with end-stage renal disease.

Transplant Evaluation and Institutional Decision-Making

The University of Miami Miller School of Medicine is specifically associated with the evaluation and management of HCV-infected kidney-transplant candidates. Chronic HCV infection before transplantation has been reported in 7–40% of kidney recipients, with variation by geography and demographic composition. In this population, HCV is intertwined with prolonged end-stage renal disease, prior transplantation, substance-abuse history, hepatitis B coinfection, and diabetes mellitus; diabetes affects about 30% of infected candidates aged 30–50 and reaches 63% among elderly candidates in the cited data.

The transplant setting requires more than a positive antibody test. In low-prevalence regions, screening begins with an enzyme immunoassay, followed by nucleic-acid testing to document viremia; in high-prevalence settings, nucleic-acid testing is recommended initially because a negative antibody assay may not reliably exclude infection. Up to one quarter of patients with active HCV infection have advanced fibrosis on liver biopsy despite otherwise well-compensated disease. Accordingly, the KDIGO workgroup recommended percutaneous liver biopsy for all HCV-infected patients being considered for kidney transplantation, since noninvasive methods had not yet demonstrated comparable accuracy and reliability.

The university’s transplant-related role also belongs to a system of continuing surveillance rather than a one-time eligibility decision. With deceased-donor waiting times in some areas of the United States approaching five to seven years, candidates require repeated assessment to ensure that liver disease has not progressed beyond suitability for kidney-alone transplantation. Patients with positive NAT results may be placed on hold and referred to a hepatologist. Those who have achieved sustained virologic response require at least annual NAT testing to confirm durability, while relapse prompts renewed specialist evaluation and possible retreatment. Candidates who remain viremic likewise require annual assessment because liver histology may worsen during the waiting period.

HCV in Renal Allografts

The University of Miami’s institutional context is further connected to the consequences of HCV after transplantation. HCV remains an independent risk factor for renal-allograft loss, although some of the adverse outcome may reflect the higher immunological risk of the infected population, including retransplantation, longer exposure to renal disease, and stronger cellular and humoral immune responses. HCV infection has also been associated with glomerulitis, transplant glomerulopathy, and antibody-mediated rejection, while autoimmune mechanisms and glomerular disease provide an additional explanation for injury.

HCV-infected renal allograft recipients may develop immune-complex-mediated glomerulonephritis, including de novo membranoproliferative glomerulonephritis. Reported manifestations include hypertension, microhematuria, proteinuria, renal dysfunction, and sometimes nephrotic syndrome. Biopsy may show mesangial proliferation, double contours, and parietal IgM and C3 deposits. Because transplant glomerulopathy can produce overlapping findings, electron microscopy may be needed: membranoproliferative glomerulonephritis is associated with subendothelial electron-dense deposits, whereas transplant glomerulopathy shows radiolucent areas in the glomerular basement membrane. The two lesions can coexist, illustrating why HCV-related autoimmunity and transplantation-related humoral injury cannot always be separated cleanly.

In this evidence network, the University of Miami represents the institutional convergence of clinical observation, specialist referral, and outcome-based research. Its connection to hepatitis C care encompasses the distinction between antibody positivity and active viremia, the often silent progression of liver disease in dialysis, the mental and physical costs of treatment, the repeated scrutiny imposed by the transplant waiting list, and the possibility of immune-complex renal injury after transplantation. The university’s significance is therefore structural: it occupies the point where viral diagnosis becomes longitudinal management across liver, kidney, patient experience, and graft survival.